[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370197-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370197-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-hgfc-met-signaling-to-regulate-the-tumor-microenvironment-implications-for-counteracting-tumor-immune-evasion","Targeting HGF/c-MET signaling to regulate the tumor microenvironment - Implications for counteracting tumor immune evasion","","Hepatocyte growth factor (HGF) and its receptor c-MET maintain normal cellular physiology, while dysregulation of c-MET signaling contributes to tumor development and progression. Although immune checkpoint inhibitors (ICIs) can achieve durable responses in some patients, preclinical evidence indicates that MET imbalance can limit anti-PD-1/PD-L1 efficacy through multiple mechanisms. This review clarifies how c-MET signaling shapes the tumor microenvironment (TME) and how anti-MET treatment affects ICI performance. Clinical and translational studies support combined c-MET and PD-1/PD-L1 inhibition, with emphasis on improved outcomes in MET tumors displaying elevated PD-L1.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-hgfc-met-signaling-to-regulate-the-tumor-microenvironment-implications-for-counteracting-tumor-immune-evasion/370197/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-hgfc-met-signaling-to-regulate-the-tumor-microenvironment-implications-for-counteracting-tumor-immune-evasion/370197.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is HGF/c-MET signaling important in cancer biology?","Question",{"text":63,"@type":64},"HGF activates the c-MET receptor to drive downstream signaling that supports tumor cell growth, proliferation, and survival. Disruption or dysregulation of this pathway promotes multiple cancer hallmarks, including invasion, metastasis, resistance to apoptosis, EMT, and angiogenesis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can MET imbalance affect anti-PD-1/PD-L1 immunotherapy?",{"text":68,"@type":64},"Preclinical studies indicate that an imbalance in MET signaling can hinder the effectiveness of anti-PD-1/PD-L1 treatments through different mechanisms, reducing the impact of immune checkpoint blockade.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the main rationale for combining c-MET inhibitors with PD-1/PD-L1 inhibitors?",{"text":72,"@type":64},"The review emphasizes that targeting c-MET together with immunotherapy improves treatment effectiveness, particularly for MET tumors with elevated PD-L1 expression, by influencing PD-L1 regulation and tumor microenvironment control.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370197,1790218645,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Xia et al. Cell Communication and Signaling (2025) 23:46  \n[https://doi.org/10.1186/s12964-025-02033-1](https://doi.org/10.1186/s12964-025-02033-1)  \nCell Communication and Signaling  \n REVIEW Open Access  \nTargeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion  \nYang Xia1,3†, Chunye Huang1,3†, Min Zhong2†, Hongguang Zhong1,3†, Ruiwen Ruan1,3, Jianping Xiong1,3, Yangyang Yao1,3*, Jing Zhou2* and Jun Deng1,3*  \nAbstract  \nThe hepatocyte growth factor (HGF) along with its receptor (c-MET) are crucial in preserving standard cellular physiological activities, and imbalances in the c-MET signaling pathway can lead to the development and advancement of tumors. It has been extensively demonstrated that immune checkpoint inhibitors (ICIs) can result in prolonged remission in certain patients. Nevertheless, numerous preclinical studies have shown that MET imbalance hinders the effectiveness of anti-PD-1/PD-L1 treatments through various mechanisms. Consequently, clarifying the link between the c-MET signaling pathway and the tumor microenvironment (TME), as well as uncovering the effects of anti-MET treatment on ICI therapy, is crucial for enhancing the outlook for tumor patients. In this review, we examine the impact of abnormal activation ofthe HGF/c-MET signaling pathway on the control oftheTME and the processes governing PD-L1 expression in cancer cells. The review thoroughly examines both clinical and practical evidence regarding the use of c-MET inhibitors alongside PD-1/PD-L1 inhibitors, emphasizing that focusing on c-MET with immunotherapy enhances the effectiveness of treating MET tumors exhibiting elevated PD-L1 expression. Keywords Cellular, Mesenchymal epithelial transition factor, Tumor microenvironment, PD, 1/PD, L1 inhibitors, c, MET inhibitors, HGF/c, MET signaling pathway  \n†Yang Xia, Chunye Huang, Min Zhong, and Hongguang Zhong contributed equally to this work.  \n*Correspondence: Yangyang Yao [yyyao@ncu.edu.cn](yyyao@ncu.edu.cn)[ ](yyyao@ncu.edu.cn)Jing Zhou [cherishingjing@163.com](cherishingjing@163.com)[ ](cherishingjing@163.com)Jun Deng  \n[dengjun19871106@ncu.edu.cn](dengjun19871106@ncu.edu.cn)  \n1 Department of Oncology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China  \n2 Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China  \n3 Jiangxi Key Laboratory for Individual Cancer Therapy, 17 Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China  \nIntroduction  \nThe MET gene, located on chromosome 7 in humans, isan oncogene comprised of 21 exons and 20 introns. Following translation and subsequent post-translational modifications, MET generates a heterodimeric receptor, c-MET, consisting of an extracellular α-chain and atransmembrane β-chain. Within the tumor microenvironment (TME), the specific ligand hepatocyte growth factor (HGF) is predominantly released by fibroblasts associated with cancer [1]. When HGF interacts with the c-MET receptor, it triggers the formation of homodimers and the autophosphorylation of tyrosine residues. The phosphorylation process at these tyrosine sites creates binding points for multiple signaling effectors such as GRB2, SHC, CRK, PI3K, PLCγ, SRC, SHIP2, and STAT3 [2]. Consequently, this initiates the activation of  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this ar","cbCaieRlTobuFVvN","https://ap.wps.com/l/cbCaieRlTobuFVvN","pdf",1501622,18,"English","# Abstract\n# Introduction","[{\"question\":\"Why is HGF/c-MET signaling important in cancer biology?\",\"answer\":\"HGF activates the c-MET receptor to drive downstream signaling that supports tumor cell growth, proliferation, and survival. Disruption or dysregulation of this pathway promotes multiple cancer hallmarks, including invasion, metastasis, resistance to apoptosis, EMT, and angiogenesis.\"},{\"question\":\"How can MET imbalance affect anti-PD-1/PD-L1 immunotherapy?\",\"answer\":\"Preclinical studies indicate that an imbalance in MET signaling can hinder the effectiveness of anti-PD-1/PD-L1 treatments through different mechanisms, reducing the impact of immune checkpoint blockade.\"},{\"question\":\"What is the main rationale for combining c-MET inhibitors with PD-1/PD-L1 inhibitors?\",\"answer\":\"The review emphasizes that targeting c-MET together with immunotherapy improves treatment effectiveness, particularly for MET tumors with elevated PD-L1 expression, by influencing PD-L1 regulation and tumor microenvironment control.\"}]","Targeting HGF/c-MET signaling to regulate the tumor microenvironment - Implications for counteracting tumor immune evasion | PDF",1790187290,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfcb3732604a96f3f67baa926c7857b8.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/049a5eede39142bacaf8983430092212.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28304a558100985ff75357131251560b.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70b96706f151ec6c37af20222803339d.webp",980,1301]